Eli Lilly and Company (NYSE:LLY) Holdings Boosted by Manning & Napier Group LLC

Manning & Napier Group LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.4% during the first quarter, HoldingsChannel.com reports. The fund owned 190,346 shares of the company’s stock after acquiring an additional 6,208 shares during the period. Manning & Napier Group LLC’s holdings in Eli Lilly and were worth $35,559,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Moody Lynn & Lieberson LLC lifted its holdings in Eli Lilly and by 16.3% in the fourth quarter. Moody Lynn & Lieberson LLC now owns 98,229 shares of the company’s stock worth $16,585,000 after acquiring an additional 13,739 shares during the last quarter. Toronto Dominion Bank increased its stake in shares of Eli Lilly and by 11.8% in the fourth quarter. Toronto Dominion Bank now owns 553,515 shares of the company’s stock valued at $93,454,000 after purchasing an additional 58,220 shares during the period. UMB Bank N A MO increased its stake in shares of Eli Lilly and by 7.4% in the first quarter. UMB Bank N A MO now owns 25,060 shares of the company’s stock valued at $4,682,000 after purchasing an additional 1,716 shares during the period. Steel Peak Wealth Management LLC increased its stake in shares of Eli Lilly and by 60.1% in the fourth quarter. Steel Peak Wealth Management LLC now owns 6,188 shares of the company’s stock valued at $1,045,000 after purchasing an additional 2,323 shares during the period. Finally, Redpoint Investment Management Pty Ltd increased its stake in shares of Eli Lilly and by 7.9% in the fourth quarter. Redpoint Investment Management Pty Ltd now owns 22,978 shares of the company’s stock valued at $3,880,000 after purchasing an additional 1,686 shares during the period. 75.59% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and stock opened at $185.92 on Tuesday. The company has a 50 day moving average price of $185.84 and a 200 day moving average price of $176.06. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. The firm has a market capitalization of $178.30 billion, a price-to-earnings ratio of 30.38, a P/E/G ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Monday, April 26th. The company reported $1.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.12 by ($0.25). The company had revenue of $6.81 billion for the quarter, compared to analyst estimates of $7.10 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the business earned $1.75 EPS. Equities analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 10th. Stockholders of record on Friday, May 14th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.83%. Eli Lilly and’s dividend payout ratio is currently 56.29%.

In other news, Director Jackson P. Tai bought 1,366 shares of the company’s stock in a transaction that occurred on Friday, April 30th. The shares were purchased at an average price of $182.84 per share, for a total transaction of $249,759.44. Following the acquisition, the director now directly owns 60,649 shares of the company’s stock, valued at approximately $11,089,063.16. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 125,284 shares of the business’s stock in a transaction dated Monday, March 8th. The stock was sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the transaction, the insider now owns 110,422,933 shares in the company, valued at approximately $23,154,584,820.77. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Several equities research analysts have commented on LLY shares. Truist raised their price target on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Cowen raised their price target on shares of Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Morgan Stanley dropped their price target on shares of Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 28th. Bank of America raised their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, January 22nd. Finally, Truist Securities raised their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, March 22nd. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Eli Lilly and has a consensus rating of “Buy” and a consensus price target of $200.75.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Story: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.